Avalo Therapeutics Inc
Research Avalo Therapeutics Inc (AVTX) on Bullrun: market cap USD 1.04B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAVTX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.04B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 36.36M
- Free cash flow-USD 19.99M
Valuation Snapshot
latest market cap is USD 1.04B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 59.00K | -USD 78.26M | -USD 51.46M | 100.0% | -5.84 | USD 15.86M | USD 392.00K | USD 83.05M |
| FY2024 | USD 441.00K | -USD 35.13M | -USD 49.06M | 182.5% | -20.91 | USD 134.55M | USD 568.00K | USD 133.03M |
| FY2023 | USD 1.92M | -USD 31.54M | n/a | 33.3% | -113.58 | USD 7.42M | USD 537.00K | USD 7.30M |
| FY2022 | USD 18.05M | -USD 41.66M | -USD 26.85M | 81.0% | -1063 | USD 13.17M | USD 19.24M | -USD 10.92M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.04B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 336.19M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 77.81M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 7.29M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 47.42M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 191.92M | n/a | n/a | n/a |
About Avalo Therapeutics Inc
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Avalo Therapeutics Inc's market cap?
Avalo Therapeutics Inc's market capitalization is USD 1.04B.
What does Avalo Therapeutics Inc do?
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.